Advancing Potency Assays for TIL Therapies to Prevent Clinical Holds & Streamline Route to Patients

Time: 11:30 am
day: Conference Day Two CMC Track AM

Details:

• Comparing the development of potency assays for CAR-Ts, TCR-Ts, ex vivo T-cell therapies and TILs, highlighting the unique challenges faced by personalized T-cell therapies like TILs
• Exploring the complexities of developing potency assays for TIL therapies, including surrogate assays and GMP-ready validation
• Discussing the difficulties in validating potency assays that accurately target the mechanism of action of TILs

Speakers:

Divya Lenkala Divya Lenkala is a leading immunologist with over a decade of experience in T cell therapy innovation. At BioNTech US, she led a team understanding Read more